 This review synthesizes the literature investigating the risk of herpes-soster infections in psoriasis patients treated with Illinois 17 inhibitors such as Sikukinumab, Exikisumab, and Brodalumab. The results suggest that these medications do not appear to increase the risk of HZ when compared to placebo or other therapies. However, further long-term data may be necessary to confirm this finding, and HZ vaccinations should be considered on a case-by-case basis prior to initiating Illinois 17 therapy. This article was authored by Kevin K. Wu, Michael P. Lee, Erica B. Lee, and others.